OrganoBiotech
OrganoBiotech develops high-throughput human organ-on-chip platforms for scalable, reproducible drug screening and disease modeling
Axion BioSystems
At Axion BioSystems, our mission is to empower scientists to reach new heights of discovery with high-quality, user-friendly lab tools that deliver powerful live-cell analysis for disease research and therapeutic discovery. Designed for continuous, noninvasive monitoring of 2D and 3D cell models in vitro from the benchtop or incubator, Axion’s user-friendly Maestro and Omni systems are indispensable tools in academic, biotechnology, and pharmaceutical labs worldwide.
innoVitro
As a CRO, innoVitro specializes in human-cell analytics for drug safety, toxicity, and efficacy in preclinical cardiac risk assessment.
Quris.AI
Quris.AI is transforming drug safety prediction by uniquely combining advanced AI capabilities with cutting edge 3D organ models, enabling predictions with unprecedented accuracy and scalability. our platform has been extensively validated by leading Pharma companies, including a long term collaboration with Merck GmbH. By predicting safety in human relevant 3D models, our platform significantly increases the likelihood of clinical success and reduces significantly the need for animal testing.
Microtissues, Inc.
Since 2010, Microtissues, Inc has been selling the 3D PetriDish, a reusable micro-mold platform system for forming multi-cellular spheroids and organoids from primary cells, cancer cells, stem cells and cell lines. Our products are distributed worldwide by Millipore Sigma and have been used in over 200 peer-reviewed publications, a list which is available on our website.
TheWell Bioscience
TheWell Bioscience provides xeno-free, 3D cell culture solutions, empowering research in organoids, regenerative medicine, and drug discovery.
Optics11
Optics11Life develops cutting-edge life science tools using optical fiber sensing technology. The two main products are: The Nanoindentation Platform (Pavone, Piuma and Chiaro) and The Cuore 3D Engineered Muscle Contractility Platform
Exir Bio
Exir Bio’s goal is to accelerate drug discovery, efficacy, and safety assessments by combining nonhuman primate (NHP) in vitro / in vivo models,
replacing, reducing, and refining (3R’s) the use of NHPs – necessary due to the global shortage of NHPs and in accordance with US Modernization Act
2.0.
Exir Bio has access to ~20,000 NHP’s / 8 species across several colonies in the US, all with known origin and bred in captivity per FDA and European
Union requirements.
STEMCELL Technologies
We are the world-leading provider of reagents and services for generating organoid and stem cell-derived models of healthy and diseased human tissues.